Company ProfilePremium

Patanjali Ayurved Limited

Company Profile Analysis

Ticker: PATANJALI.NS

ESOMAR 23 Corporate BadgeISO Certifications Badge
Patanjali Ayurved Limited - Company showcase

Year Founded & Workforce

2006

4,629 Employees

Patanjali Ayurved Limited logo

Patanjali Ayurved Limited Employee Contacts

46 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Patanjali Ayurved Limited Overview

Patanjali Ayurved Limited is the privately controlled flagship and brand-owning holding company of the Patanjali Group, the Haridwar-based Ayurveda-and-swadeshi consumer conglomerate co-founded by Acharya Balkrishna and Swami Ramdev. From incorporation in 2006, PAL scaled into one of India's fastest-growing FMCG companies by the mid-2010s. It did so on value pricing, Ayurvedic and herbal positioning, and Ramdev's mass yoga following. It reached roughly ₹10,000 crore of standalone revenue by FY2017 and peaked at ₹10,664 crore in FY2022. Since 2019 the company has re-engineered itself around its listed vehicle, Patanjali Foods, through three steps:

  • acquiring the insolvent Ruchi Soya;

  • transferring its food (2022) and home-and-personal-care (2024) businesses into PFL;

  • retaining brand ownership, Ayurvedic wellness, dairy, trading and strategic investments.

PAL is now pivoting into financial services via a ₹4,500 crore (100% valuation) acquisition of Magma General Insurance. It remains under heavy regulatory and judicial scrutiny over its advertising practices.


Company's own description

The Secretarial Audit Report annexed to PAL's FY2021-22 Annual Report describes PAL as follows:

  • an FMCG business spanning Ayurvedic products, foods and refreshment, home care, personal care and dairy products;

  • with manufacturing facilities across India;

  • selling primarily in India through independent distributors and exclusive stores.

The Board's Report frames the proposition as Ayurvedic, herbal, traditional and domestic products at reasonable prices, with profit described as not being the sole motive. In RoC-based reporting for FY2024, PTI described PAL's operations as follows:

  • the Ayurvedic product and FMCG business, primarily hair care, skin care, dental care, home care, personal care and dairy products;

  • plus bulk trading of food products.

Independent characterisation (as of October 2026)

PAL's business model has changed fundamentally since FY2022. It is best understood today as a hybrid of four things:

  1. Brand-owning parent and promoter. PAL owns the "Patanjali" consumer franchise and is the single largest promoter of PFL. It held 29.61% of PFL at March 2026 (marketsmojo shareholding data). It earns from PFL through several channels:

    • related-party sales and purchases (PFL's AGM in September 2025 approved a revised material related-party transaction limit with PAL for FY2025-26);

    • royalties;

    • divestment proceeds — ₹690 crore for the food business in 2022, ₹1,100 crore for the HPC business in 2024, and OFS/secondary sales of PFL shares.

  2. Residual operating FMCG/Ayurveda company. After two business transfers, PAL's revenue from operations fell from ₹10,664 crore (FY2022) to ₹6,460 crore (FY2024). A third-party aggregator reports ₹5,856 crore for FY2025. What remains appears to include:

    • Ayurvedic and wellness products, a large share of which are manufactured by group trust entity Divya Pharmacy (Divya Yog Mandir Trust) and marketed under the Patanjali/Divya brands;

    • dairy;

    • bulk trading;

    • intra-group supply. The exact post-2024 product perimeter is not publicly disclosed.

  3. Strategic investor/diversifier. Its interests span:

    • general insurance (Magma General Insurance, 73.56% to be acquired; IRDAI approval 28 July 2026);

    • food parks (Nagpur MIHAN; Vizianagaram);

    • wellness and hospital initiatives (with Patanjali Yogpeeth);

    • education/research linkages.

  4. Financier within the group. Its FY2022 audited statements disclose interest-free loans, advances and corporate guarantees to group companies and other entities.

Revenue model and mix

Product vs. service: Historically almost entirely product revenue (FMCG goods sold through distributors, modern trade, e-commerce and exclusive Patanjali stores).

Licensing/royalty: PAL received ₹5.04 crore of royalty in FY2022 on contract-manufactured products sold by PFL. It also received ₹3.55 crore for transferring the right to sell biscuits, breakfast cereals, edible oil and nutraceuticals to PFL with effect from 2 June 2021 (PAL AR FY2021-22).

Investment/other income: This became material in FY2024. Other income of ₹2,875.29 crore that year included proceeds from the Offer for Sale of PFL shares and income from group entities (PTI/Tofler, FY2024). Subscription and service revenue: none disclosed.

Value-chain position, customers and end-markets

DimensionDetail
Customer typesMass-market Indian households (urban and rural); price-sensitive consumers; wellness-oriented consumers; institutional channels (e.g., defence canteen stores historically); export buyers (minor)
End-marketsAyurvedic OTC/wellness, oral care, hair and skin care, home care, dairy (ghee), health foods. After 2022 the food categories sit in PFL.
Distribution reach (company claim, 2025)Products available at ~200,000 retail counters, national chains (Reliance Retail, HyperCity, Star Bazaar) and ~250 Patanjali Mega Stores. Source: Patanjali spokesperson statement quoted in Hindu BusinessLine, March 2025.

PAL is vertically integrated across:

  • herb sourcing and contract farming (GlobalData profile);

  • manufacturing (Haridwar complex; previously Newasa, Maharashtra; Tezpur, Assam);

  • branding and distribution.

Strategy

Stated strategic themes

PAL publishes no investor-day material. Its stated strategy derives from founder statements and annual-report language:

  1. Swadeshi Ayurveda at value prices. Ayurvedic, herbal, traditional and domestic products at reasonable prices, with profit described as not the sole motive (Board's Report FY2022).

  2. Vision 2027 (16 Sep 2022). Ramdev announced:

    • IPOs of four group companies within five years: Patanjali Ayurved first, then Patanjali Medicine (described as owning Divya Pharmacy), Patanjali Wellness and Patanjali Lifestyle;

    • a target of ₹5 lakh crore combined market value for five listed entities, including PFL;

    • group turnover rising from ~₹40,000 crore to ₹1 lakh crore in 5–7 years;

    • PFL to target ₹5,000 crore EBITDA and become India's largest oil-palm plantation company;

    • more than 5 lakh jobs.

  3. Group restructuring around PFL. PAL has consolidated food (2022) and HPC (2024) into the listed vehicle, so that PFL is the FMCG operating platform and PAL retains brand ownership, Ayurveda and new ventures.

  4. Diversification into financial services and healthcare. This takes the form of the Magma General Insurance acquisition (2025–26) and hospitals/wellness (Jan 2026).

  5. Agro-processing and farmer linkage. Mega food parks are framed as "agriculture revolution" projects for Vidarbha (Nagpur) and North Andhra (Vizianagaram).

Initiatives in the last 24 months (Oct 2024 – Oct 2026)

DateInitiativeTypeDetail
2024 (completed FY2025)HPC business sale to PFL (₹1,100 crore)Portfolio restructuringDental, skin, home and hair care moved to PFL
9 Mar 2025Nagpur MIHAN Mega Food & Herbal ParkCapacity/agro-processing₹1,500 crore; 800 tpd; zero-waste orange processing
12 Mar 2025Magma General Insurance SPANew business (insurance)₹4,500 crore valuation; PAL 73.56%
Jun 2025Vizianagaram mega food park revivalCapacity172.84 acres (APIIC)
2,025Patanjali Organic Research Institute founded (by Balkrishna)R&D/agriGroup-level
Dec 2025MoU with the Russian governmentInternationalHealth, wellness and tourism
Dec 2025Tripura government partnershipRegional investment₹300–400 crore project
22 Jan 2026Patanjali Emergency & Critical Care HospitalHealthcareDescribed as a hybrid heart, brain and spine care hospital
28 Jul 2026IRDAI approval for MagmaRegulatory milestoneCompletion window of three months

Sustainability/ESG commitments

No formal emissions, net-zero or ESG targets are publicly disclosed by PAL. Energy measures disclosed in FY2022:

  • 8.3 MWp rooftop solar;

  • boiler fuel substitution with waste herbs (₹77.22 lakh saving);

  • open-access power trading (₹10.23 lakh saving);

  • VFDs and compressed-air optimisation.

Medium-term financial targets/guidance

PAL: no formal guidance. The Vision 2027 aspirations above are founder statements rather than formal company guidance.

PFL (management guidance, FY2027): edible-oil volume growth 3–5%; foods 8–10%; HPC ~15%; HPC margin ~18% or higher; foods margin approaching ~10%; edible oils slightly below 4% (ScanX; The Consumer Daily, May–June 2026). PFL's CEO targeted 10–12% HPC growth and 6–8% foods growth for FY2026 (CNBC-TV18, Dec 2025).

Products & Services

PAL does not publish a SKU-level catalogue with launch years or pricing in its statutory filings. The catalogue below is compiled from company statements, court records and media. Entity attribution after 2022/2024 is uncertain. Many Patanjali-branded food and HPC products are now sold by PFL, and Ayurvedic medicines are largely manufactured by Divya Pharmacy (a trust undertaking).

Ayurvedic & wellness (retained/brand-level; manufacturer often Divya Pharmacy)

Product / lineDescription & positioningStatus / notes
Patanjali Special ChyawanprashClassical Ayurvedic immunity tonic. Patanjali claims 51 herbs plus saffron based on Ayurved Sar Sangrah.Subject of Dabur injunctions (3 Jul 2025; 6/11 Nov 2025). The 2025 appeal was filed by PAL together with PFL, indicating shared involvement.
Divya Coronil (tablet/kit)Marketed in June 2020 as a COVID-19 cure (kit ₹545). Later permitted only as an immunity booster/"supporting measure."Madras HC barred use of the "Coronil" mark and imposed a ₹10 lakh fine (Aug 2020)
Lipidom, Livogrit, Livamrit (Advance)Ayurvedic formulations marketed for lipid/liver conditionsAYUSH Ministry sought action against ads (Apr 2022). Reported among 14 licences suspended in Apr 2024.
BP Grit, Madhugrit, Madhunashini Vati Extra PowerFormulations positioned for blood pressure and diabetesReported among the 14 suspended licences (Apr 2024)
Swasari range (Gold, Vati, Pravahi, Avaleh), Bronchom, Mukta Vati Extra PowerRespiratory and BP-related formulationsReported among the 14 suspended licences (Apr 2024)
Eyegrit Gold, Patanjali Drishti eye dropEye-care formulationsReported among the 14 suspended licences (Apr 2024)
Divya Putrajeevak BeejHerbal product for infertilityRaised in Parliament (Jul 2015); Uttarakhand health department alleged PCPNDT violation (2016)
Honey, Aloe vera, Amla juiceWellness staplesAmla juice withdrawn by Defence CSD after adverse lab report (Apr 2017)

Pricing model. Mass-market value pricing positioned below multinational equivalents. Specific price lists are not disclosed.

Home & personal care (transferred to PFL in 2024; brand owned by group)

Product lineFlagship brandsNotes
Oral careDant Kanti toothpastePAL's toothpaste share was reported at 9.62% on a 12-month trailing basis to April 2021 (BloombergQuint)
Hair careKesh Kanti shampoo/oilPart of the HPC transfer
Skin careSaundarya range; soaps; cosmeticsPart of the HPC transfer; ASCI notices on hair oil (2016)
Home careDetergents, dishwash, cleanersPart of the HPC transfer

Scale reference: HPC revenue was ₹2,475 crore in FY2021 at PAL (BloombergQuint) and ₹627 crore in Q3 FY2026 at PFL (AlphaStreet).

Foods & dairy (transferred to PFL in 2021–2022)

Product lineFlagship offeringsNotes
Cow gheePatanjali Cow GheeNewasa unit transferred to PFL in 2022. Ghee revenue in PFL was ₹467 crore in Q3 FY2026.
BiscuitsDoodh biscuitDoodh crossed ₹1,300 crore annual sales in PFL (FY2026)
Staples, cereals, noodlesAtta noodles (launched Nov 2015), breakfast cerealsBiscuit/noodles business moved to Ruchi Soya in 2021
NutraceuticalsNutrela-linked range (PFL)Nutraceuticals turned profitable in H1 FY2025 (PFL)
BeveragesGulab sharbat; fruit juices (Nagpur plant output)"Sharbat jihad" litigation (Apr–May 2025)

Adjacent and non-FMCG offerings (group level)

OfferingDescriptionEntity / status
Patanjali ParidhanApparel retail (store opened Delhi Nov 2018)Group company
Swadeshi Samriddhi SIMCo-branded BSNL SIM (May 2018)Partnership
Co-branded prepaid cardOpen-loop prepaid card with Ongo (Mar 2024)GlobalData profile
Magma General Insurance70+ general insurance products: motor, health, home, personal accident, fire, engineering, marine, liabilityPAL to hold 73.56% on completion
Wellness & hospitalsPatanjali Wellness centres; Patanjali Emergency & Critical Care Hospital (Jan 2026)Overseen by Patanjali Yogpeeth per Balkrishna profile
Food processing (B2B/B2C)Nagpur park: orange and other fruit juices, peel oils, pulps, ketchup, jams, pickles (800 tpd)PAL / PFHP Nagpur subsidiary

Financial Detail

Group Entities

EntityRelationship to PALHoldingNotes

Patanjali Food & Herbal Park Nagpur Pvt Ltd

Subsidiary

99.90%

Total assets ₹466.56 cr (FY2022); vehicle for the Nagpur MIHAN park

Patanjali Food & Herbal Park Noida Pvt Ltd

Subsidiary

99.92%

Total assets ₹194.36 cr (FY2022)

Patanjali Food & Herbal Park Jammu Pvt Ltd

Subsidiary

99.99%

Dormant shell (assets ₹0.12 cr)

Patanjali Food & Herbal Park Pvt Ltd

Associate

49.07%

Associated since 30-Mar-2009

Patanjali Food & Herbal Park Andhra Sansthan

Associate

49.00%

Associated since 04-Aug-2017

Patanjali Foods Ltd (formerly Ruchi Soya)

Associate

48.17% (Mar 2022), then 29.61% (Mar 2026)

Listed; reduced via FPO dilution, July 2023 OFS and 2025 secondary sales

Revenue by Segment and Segment Margins & Growth (%)

Segment (INR Cr)FY2020FY2021

Food & dairy products revenue (FY2020 derived)

6,5516,348

Home & personal care revenue (FY2020 derived)

1,9862,475

Ayurvedic products revenue (FY2020 derived, ≤)

425850

Other goods revenue (FY2020 derived)

67111

Segment metric (%)

FY2021

—

Food & dairy YoY growth

-3.1—

Home & personal care YoY growth

24.6—

Ayurvedic products YoY growth (company: "more than doubled")

100—

Other goods YoY growth

65.6—

Food & dairy share of revenue (computed)

64.9—

HPC share of revenue (computed)

25.3—

Ayurvedic share of revenue (computed)

8.7—

Operating margin, company level

10.6—

Segment Margins & Growth (%) and Revenue by Segment

PFL segment (INR Cr)FY2025FY2026

Edible oils revenue (FY2025 derived from reported 18.39% growth)

24,76029,313.54

FMCG revenue, incl. food, biscuits, HPC (FY2025 derived from reported 19.95% growth)

9,32711,188.25

Oil palm plantation revenue

—1,792.58

Total revenue from operations

33,758.2540,169.58

PFL segment metric (%)

FY2026

—

FMCG share of revenue

27.60—

FMCG share of EBITDA (ex-unallocable)

61.13—

FMCG EBITDA margin

10.81—

Q4 FY2026 edible oil EBITDA margin

2.58—

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue from operations (INR Cr)

9,810.7410,664.467,533.886,460.035,855.69

Other income (INR Cr)

61.1366.4946.182,875.29—

Total income (INR Cr)

9,871.8710,730.957,580.069,335.32—

Total expenditure before depreciation (INR Cr)

9,060.069,992.36———

Profit before depreciation & tax, EBITDA proxy (INR Cr)

811.81738.59———

Depreciation (INR Cr)

172.63145.41———

Profit before tax (INR Cr)

639.18593.18———

Tax expense (INR Cr)

154.62161.38———

Net profit after tax (INR Cr)

484.56431.80578.442,901.10—

EPS basic, computed on 4,13,22,108 shares (INR)

117.26104.50139.98702.07—

Dividend per share (INR)

—0———

Advertising & promotion, PTI series (INR Cr; FY2023 derived)

——386.46422.33—

Advertising & promotion, afaqs series (INR Cr)

——173.13424.70—

CSR spend (INR Cr)

—11.38———

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue growth YoY (%)

8.218.70-29.35-14.25-9.36

PBDT (EBITDA-proxy) margin (%)

8.276.93———

PBT margin (%)

6.515.56———

Net margin on revenue from operations (%)

4.944.057.6844.91—

Other income as % of total income (%)

0.620.620.6130.80—

Balance Sheet

MetricFY2021FY2022FY2023FY2024FY2025

Paid-up equity share capital (INR Cr)

41.3241.32———

Equity shares outstanding (crore shares)

4.13221084.1322108———
—2504254251750

Loans to directors and relatives outstanding during year, later recovered (INR Cr)

—22.83———

GST demand deposited under protest (INR Cr)

—75.09———

Key Financials

MetricFY2021FY2022

Dividends paid (INR Cr)

—0

Share buybacks (INR Cr)

00

Foreign exchange outgo on capital goods and services (INR Cr)

—52.14

Margin Analysis (%) (FY2022)

RatioFY2022

R&D as % of revenue (%)

0.0004

Income Statement

MetricFY2022FY2023FY2024FY2025FY2026

PFL revenue from operations (INR Cr)

——31,72133,758.2540,169.58

PFL total income (INR Cr)

—31,821.4531,961.6234,289.4040,347.78

PFL net profit (INR Cr)

740.38886.44765.151,301.341,814.47

PFL EBITDA excluding exceptional items (INR Cr)

————1,931.52

Region (INR Cr) Overview

Region (INR Cr)FY2022

Export earnings, accrual basis

67.32

Domestic revenue (derived: revenue from operations less exports)

10,597.14

Export share of revenue (%, computed)

0.63

Country Overview

CountryActivityStatusSource

India

Core market; all manufacturing and distribution

Active

PAL AR

Nepal

Herbal factory/herbal park plans (2015); Nepal's drug regulator rejected six Patanjali products (2017); Nepal halted distribution of donated Coronil kits (2021)

Mixed

Webdunia; Firstpost; The Hindu

Bhutan

Halted distribution of donated Coronil (2021)

—

Wikipedia

United Kingdom

UK regulator warned of action against unauthorised Coronil sales (2020)

Regulatory caution

BBC

United States

USFDA flagged different dietary/medicinal claims on Patanjali products

Regulatory caution

—

Russia

MoU with the Russian government to promote health, wellness and tourism (Dec 2025)

Early-stage

Economic Times (6 Dec 2025)

Middle East

Listed as an area served

Not quantified

Wikipedia

Pfl Market Metric Details

PFL market metricValueDateSource

Share price

₹343.40

27 Jul 2026

Kotak Neo

52-week / six-year low

₹328.05–₹328.20

15 Jul 2026

Business Today; Angel One

1-year price change (%)

-46.64

to 27 Jul 2026

Kotak Neo

6-month price change (%)

-32.8

to 27 Jul 2026

Kotak Neo

YTD 2026 change (%)

approx. -37.5

to 15 Jul 2026

DSIJ / Bajaj Broking

Market capitalisation

~₹37,132 crore

15 Jul 2026

Business Today

Market capitalisation at peak period

~₹65,000 crore (Sep 2025); reported peak ~₹73,000 crore

Sep 2025

Business Today; The Consumer Daily

P/E (trailing)

~24.4x (from ~30x in May 2026)

Jul 2026

askfuzz (secondary)

PAL's direct stake

29.61%

Mar 2026

marketsmojo

PAL look-through value of PFL stake (computed)

~₹10,995 crore

15 Jul 2026

29.61% × ₹37,132 crore

Promoter group holding

68.25%

Jun 2026

Outlook Business

PFL long-term credit rating

ICRA AA- (Stable), upgraded

30 Jun 2026

PFL filing via FilingReader

Analyst stance

Mixed. Some BUY calls at ₹700 target (early 2026); ICICI Securities cut its FY2027 EPS estimate by ~14% (mid-2026).

2026

askfuzz; The Consumer Daily

PFL dividend per share (INR)

PFL dividend per share (INR)FY2024FY2025FY2026

Total dividend per share (FY2024 and FY2025 pre-bonus; FY2026 post-2:1 bonus)

14105

Credit Ratings

AgencyRating / actionDateStatus

ICRA

Upgraded A- → A+ (Stable), ₹300 crore fund-based; A2+ → A1 short-term

Jan 2017

Historical

Brickwork

AA- (Stable)

2016

Historical

CARE

Downgraded A+ → A- (credit watch, developing implications); then withdrawn at company request

Oct 2019

Withdrawn

ICRA

Downgraded to BBB, citing lack of adequate information

Oct 2019

Historical

Brickwork

Outlook revised to negative; PFHP Nagpur (PAL-guaranteed) cut to BBB+ (CE)

Oct–Nov 2019

Historical

Moody's / S&P / Fitch

Not rated

——

Capital Instruments

InstrumentAmount (INR Cr)Coupon (%)IssueMaturityStatus

Secured listed NCD

25010.10

29 May 2020

28 May 2023

Scheduled redemption passed

Secured listed NCD

1759.25

19 May 2021

18 May 2024

Scheduled redemption passed

Bank facilities (PNB-led consortium)

————

Secured partly by promoter share pledge (FY2022)

“—” = not publicly disclosed.

Analyst Conclusions

Management guidance

PAL issues no formal guidance. Founder-level aspirations (Vision 2027) remain the only stated targets:

  • four IPOs by ~2027;

  • ₹1 lakh crore group turnover within 5–7 years of 2022;

  • ₹5 lakh crore combined market value.

By the evidence, these targets are materially behind schedule. PFL's market capitalisation was ~₹37,000 crore in July 2026, and no PAL DRHP has been located. Consensus estimates for PAL do not exist. For PFL, management guides FY2027 volume growth of 3–5% in edible oils, 8–10% in foods and ~15% in HPC.

Bull case

#ArgumentEvidence
1Sum-of-parts upside. A recovery in PFL plus completion of Magma could re-rate PAL's net asset value.PFL earnings have held up: Q1 FY2027 PAT +86% YoY; ICRA upgraded to AA- (Jun 2026). Magma premiums grew 22% CAGR over FY2021–FY2025.
2Distribution flywheel into insurance. Cross-selling simple motor/health covers through ~200,000 counters could scale Magma from its ~1% share.Company distribution claims (Mar 2025); Magma's 70+ products
3Asset-light parent with crystallised cash. Sales have realised roughly ₹3,600 crore or more since 2022 (₹690 crore + ₹1,100 crore + ₹1,815 crore + OFS proceeds), while debt matured.PAL AR; PTI; Outlook Business

Bear case

#ArgumentEvidence
1Shrinking, low-margin core. Revenue from operations is down ~45% from its FY2022 peak. Historical PBT margins were 5–6%, and FY2024 profits were inflated by one-offs.Section 6
2Escalating legal and regulatory drag. Four court restraints on advertising in two years, a reported MCA probe and multiple state DMR Act cases constrain the founder-led marketing model.Section 19
3Concentration and governance. About 98.5% of PAL is owned by one individual, roughly half of it pledged. Disclosure is opaque, with auditor-flagged director loans. The single largest asset (PFL) fell ~47% in a year. Insurance requires fit-and-proper governance and ongoing capital.PAL AR FY2022; Kotak Neo

Catalysts and monitorables (next 12 months)

  1. Completion of the Magma acquisition within the IRDAI window (~28 Oct 2026); funding mix; capital infusion; board reconstitution.

  2. PAL FY2026 RoC financials (expected late 2026). Watch for confirmation of FY2025/FY2026 revenue classification, other income, net debt and Magma funding.

  3. PFL quarterly results. Edible-oil margin trajectory (Q4 FY2026 EBITDA margin was 4.0%); HPC growth; dividend policy.

  4. Litigation outcomes. Dabur appeals and suits; Hamdard contempt; any MCA action; Kerala cases.

  5. IPO signals under Vision 2027 (DRHP filing or banker mandates).

  6. Further PFL stake sales or block deals by the promoter group (block deals of 1.48% in Feb 2026 and 1.5% in Jul 2026).

Analyst verdict

Patanjali Ayurved Limited is no longer the company that unsettled Indian FMCG in 2016. It has moved from operating champion to holding company. Between 2019 and 2024, management executed a coherent if self-serving restructuring:

  • it bought Ruchi Soya out of insolvency for ₹4,350 crore;

  • it used that listed shell to absorb Patanjali's food (₹690 crore) and home-and-personal-care (₹1,100 crore) franchises;

  • it sold down PFL shares to meet public-float rules, booking ₹2,875 crore of other income in FY2024 alone.

The result is a parent whose operating revenue has roughly halved from its FY2022 peak. Its economic value now rests on three pillars:

  1. a 29.6% stake in a commodity-heavy listed affiliate;

  2. a pending controlling stake in a sub-scale general insurer;

  3. a residual Ayurvedic and dairy business whose margins have historically been a third or less of peers'.

The bull thesis depends on PFL re-rating and on Patanjali's rural distribution transforming Magma. Both are plausible, but neither is yet evidenced. PFL's FY2026 headline profit relied on a ₹788 crore tax refund, and its edible-oil margins have compressed. Patanjali has no insurance operating history, and Magma will need solvency capital.

The bear thesis is better documented:

  • the founder-centric marketing model has been repeatedly curtailed by the Supreme Court and the Delhi High Court;

  • governance markers (pledged promoter equity, auditor-flagged director loans, related-party CSR, a reported MCA inquiry) remain weak;

  • disclosure is too thin for institutional underwriting.

The Vision 2027 promises of four IPOs and ₹5 lakh crore in combined market value look unattainable on current trajectory.

Verdict: PAL is best viewed as a closely held, governance-discounted holding company with real but volatile asset value. That value is roughly ₹11,000 crore in PFL alone at July 2026 prices. Execution on Magma, legal normalisation and a transparent IPO-grade disclosure regime are the three conditions for any sustained re-rating. Until then, counterparties should price in elevated legal, governance and key-person risk.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenure / appointmentBackgroundAge / DOBRemuneration

Acharya Balkrishna

Managing Director (also described as Chairperson & CEO); promoter, ~98.5% shareholder

Co-founder, 2006

Sanskrit scholar and Ayurveda researcher. General Secretary of Patanjali Yogpeeth, Divya Yog Mandir Trust, Patanjali Research Foundation and Patanjali Gramodhyog Trust. Non-executive Chairperson of PFL (director since 18-Dec-2019). Forbes estimated his net worth at US$2.3bn (May 2021).

Born 1972 (25 Jul per NSE filing; 4 Aug per Wikipedia, a discrepancy)

Nil — PAL pays no remuneration or sitting fees to any director (AR FY2021-22)

Swami Ramdev

Co-founder, public face and strategic decision-maker; holds no equity and no board seat at PAL

—

Yoga guru; director of PFL (re-appointed at PFL's Sep 2025 AGM)

—

Not applicable

Ram Bharat

Non-Executive, Non-Independent Director

On board as of FY2022 and listed in 2026 profiles

Reported to be Swami Ramdev's brother; group executive

—

Nil

Rakesh Mittal

Non-Executive, Non-Independent Director; Chair of CSR and NRC committees (FY2022)

Re-appointed by rotation, Sep 2022

——

Nil

Ajai Kumar Arya

Independent Director

On board FY2022; listed in 2026 profiles

——

Nil

Dr. Sumedha

Independent Director

———

Nil

Sadhvi Devvarenya

Independent Director (term 22-Jul-2022 to 21-Jul-2027)

Appointed 22 Jul 2022

B.E. (Electronics & Communication), Osmania University; M.A. from University of Patanjali

31 (in 2022)

Nil

Swami Arshdev

Non-Executive Director

———

Nil

Rajneesh Mishra

Non-Executive Director

Listed in GlobalData profile (2025–26)

———

Y. D. Arya

Chief Financial Officer

KMP as of FY2022

——

₹39.05 lakh (FY2022), up 7.5%

Vineet Pant

Company Secretary

KMP as of FY2022

FCS

—

₹7.42 lakh (FY2022)

Kamal Nayan Singh

Former CEO; briefly Additional Director (15 Apr–25 May 2022)

CEO from 12 Feb 2018

A.T.I. (Manchester); 33 years' experience; previously Creative Group, Mumbai

56 (FY2022)

₹1.15 crore (FY2022)

Anita Nayyar

Chief Operating Officer

—

Former media-agency executive

——

Saikat Dutta

COO, Patanjali Media

Since 2023 (GlobalData)

———

“—” = not publicly disclosed.

Board & Management Changes

DateChangeContext

15 Apr 2022

Kamal Nayan Singh appointed Additional Director

Resigned 25 May 2022 for personal reasons

13 May 2022

Swami Muktanand (Executive Director, Audit Chair, promoter shareholder) died

His 1,000 shares were transferred to Yogakshem Sansthan (27 Jul 2022)

22 Jul 2022

Sadhvi Devvarenya (Independent) and Swami Arshdev (Non-Executive) appointed

Regularised at the Sep 2022 AGM

2023 onward

Saikat Dutta named COO, Patanjali Media

GlobalData

Major Shareholders

HolderSharesStakeDateSource

Acharya Balkrishna

4,07,19,912

98.54%

31 Mar 2022

PAL AR FY2021-22

Swami Muktanand (deceased) → Yogakshem Sansthan

1,0000.002%

27 Jul 2022

PAL AR FY2021-22

Others (individuals/group entities)

Balance

~1.46%

31 Mar 2022

Derived

Institutional investors

—0%—

Unlisted; no institutional capital disclosed

Competitive Landscape

Competitors by Segment

SegmentCompetitorsNotes

Ayurvedic OTC / health supplements (chyawanprash, honey, tonics)

Dabur India; Emami (Zandu); Baidyanath; Himalaya Wellness; Hamdard (Unani/beverages); Kapiva

Dabur holds ~60–61% of the >₹1,000 crore chyawanprash market (Storyboard18; Exchange4media, 2025)

Oral care

Colgate-Palmolive (India); Hindustan Unilever; Dabur (Red, Meswak)

Dant Kanti reached ~9.6% toothpaste share (12M to Apr 2021)

Hair & skin care

HUL; Emami; Marico; Dabur; Himalaya; Godrej Consumer

HUL launched "Lever Ayush" (c.2016) in response to Patanjali

Home care

HUL; Jyothy Labs; Godrej Consumer; Reckitt

—

Dairy / ghee

Amul (GCMMF); Mother Dairy; state cooperatives

Ghee sits mostly in PFL post-2022

Foods (via PFL)

Britannia, ITC, Nestlé India, Adani Wilmar/AWL Agri Business

Edible oils, biscuits, staples

General insurance (Magma)

ICICI Lombard, Bajaj Allianz/General, New India Assurance, HDFC ERGO, Tata AIG and others

Magma share ~1.05%

Peer Comparison FY2026

CompanyFiscal yearRevenue from operations (INR Cr)YoY growth (%)Operating/EBITDA margin (%)Net margin (%)R&D intensity (%)Source

Patanjali Ayurved (standalone)

FY2024 (latest verified)

6,460.03-14.25—

44.91 (other-income distorted); FY2022 core 4.05

0.0004 (FY2022)

PTI/Tofler; PAL AR

Dabur India (consolidated)

FY2026

13,1935.0

18.6 (operating)

14.4—

Dabur AGM presentation via Investywise; Stockanalysis

Emami (consolidated)

FY2026

3,779.5-0.8

25.5 (EBITDA)

20.5—

Emami filings via FPJ/FilingReader

Colgate-Palmolive (India)

FY2026

5984 (net sales)

————

Reuters via Zerodha

Patanjali Foods (affiliate)

FY2026

40,169.5819.0

4.8 (EBITDA ex-exceptional, computed)

4.5—

PFL filings

“—” = not publicly disclosed.

Recent Developments

--

Company Snapshot

$676.2M

Revenue

4,629

Employees

2006

Founded

Haridwar, India

Headquarters

SWOT Analysis

Strengths

  • Brand scale achieved quickly. Turnover rose from ~₹51 crore in FY2008 to ₹9,784 crore by FY2021 (PAL AR FY2020-21).
  • Monetisable listed stake. PAL holds 29.61% of PFL (Mar 2026), worth roughly ₹11,000 crore even at PFL's July 2026 trough (computed from a ₹37,132 crore market cap).
  • Proven ability to realise cash from restructuring. Proceeds include ₹690 crore (2022), ₹1,100 crore (2024) and ₹1,815 crore from a single 2.71% PFL sale (2025).
  • Profitable through the cycle. PAT was positive in every disclosed year: ₹424.72 crore (FY2020), ₹484.56 crore (FY2021), ₹431.80 crore (FY2022), ₹578.44 crore (FY2023).
  • Distribution depth. Company-stated reach is ~200,000 counters, national chains and ~250 Mega Stores (Mar 2025).
  • Physical asset base. This includes Asia's self-described largest orange-processing plant (800 tpd, ₹1,500 crore, Nagpur) and the Haridwar food and herbal park complex with 8.3 MWp of solar.

Weaknesses

  • Low margins vs. peers. FY2022 PBT margin was 5.56%, against Dabur's 18.6% operating margin and Emami's 25.5% EBITDA margin in FY2026.
  • Negligible in-company R&D. ₹0.04 crore in FY2022.
  • Concentrated, pledged ownership. Balkrishna held 98.54%, of which 2.07 crore shares (~50% of equity) were pledged to PNB (FY2022).
  • Governance gaps. These include an executive director chairing the Audit Committee (FY2022) and ₹22.83 crore of loans to directors and relatives flagged by auditors (later recovered). CSR was routed to related-party Patanjali Yogpeeth Trust.
  • Shrinking operating revenue. Revenue fell −29.4% (FY2023), −14.25% (FY2024) and −9.4% (FY2025).
  • Disclosure opacity. CARE withdrew its ratings (2019) and ICRA cited lack of adequate information when downgrading to BBB (Oct 2019).

Opportunities

  • Insurance cross-sell. Magma (GWP ₹3,615 crore FY2026; 22% CAGR FY2021–FY2025) could leverage Patanjali's rural reach.
  • IPO under Vision 2027. A listing could unlock valuation and provide institutional capital.
  • Ayurveda-friendly regulation. The Supreme Court (Aug 2025) upheld repeal of Rule 170 on AYUSH ads, easing one regulatory constraint.
  • Agro-processing and farmer linkage. This includes the Nagpur citrus park, the Vizianagaram revival and the Tripura MoU.
  • International wellness. This includes the Russia MoU (Dec 2025) and the herbal beauty market growth estimated at 9.2% CAGR.
  • Healthcare services. The hospital opened in January 2026, and Vision 2027 envisions scaling wellness capacity to 25,000 patients/beds.

Threats

  • Judicial curbs on advertising. These include the Supreme Court contempt case (2024), Dabur injunctions (3 Jul 2025 and 6/11 Nov 2025) and the Hamdard injunction and contempt finding (Apr–May 2025).
  • Regulatory and enforcement exposure. This includes the reported MCA notice (May 2025), DGGI GST notices (Apr 2024), 26 Kerala DMR Act cases (Feb 2025) and the 14 licence suspensions (Apr 2024).
  • Affiliate value erosion. PFL fell ~46.6% over the year to 27 Jul 2026 and hit a six-year low, cutting PAL's look-through net asset value.
  • Competitive retaliation. Category leaders with deeper margins and R&D, such as Dabur with ~60% of chyawanprash, are litigating aggressively.
  • Execution risk in an unfamiliar regulated industry. PAL would control an insurer requiring solvency capital injections, with no insurance management track record.
  • Key-person and political-perception risk tied to founder statements (the "sharbat jihad" remarks; allopathy controversies leading to IMA notices in 2021).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
15–17 Apr 2025CCI approves (green channel) acquisition of 98.055% of Magma General Insurance by PAL and five foundationsFirst regulatory clearance for the insurance entry
22 Apr 2025Delhi HC, in Hamdard's suit, calls Ramdev's "sharbat jihad" remark against Rooh Afza indefensible; videos to be removedReputational/communal-speech risk; suit named PFL
1 May 2025Delhi HC finds Ramdev in prima facie contempt for a subsequent videoEscalation of litigation risk tied to founder conduct
30 May 2025Bloomberg reports an MCA notice to PAL over transactions flagged as abnormal/dubious by a federal economic intelligence unit (fund diversion, governance)Governance overhang; PFL shares fell ~3.9%
1–2 Jun 2025PAL (via PFL filing) denies receiving any MCA communication; legal counsel examining actionUnresolved; outcome not public
Jun 2025Uttarakhand (Nainital) HC quashes criminal case against PAL, Ramdev and Balkrishna over misleading advertisementsLegal relief
27 Jun 2025Vizianagaram mega food park revival announcedCapacity expansion
3 Jul 2025Delhi HC (Justice Mini Pushkarna) grants Dabur an interim injunction; Patanjali must delete/modify "ordinary chyawanprash" ad linesRestricts comparative advertising
17 Jul 2025PFL announces first-ever 2:1 bonus issueAffiliate liquidity
14 Aug 2025Supreme Court closes the IMA plea and upholds repeal of Rule 170 on AYUSH adsRegulatory clarity for the AYUSH sector
11 Sep 2025PFL bonus record date; 72.5 crore bonus shares; market cap ~₹65,000 croreAffiliate valuation peak region
Sep 2025PFL signs MoU with the Ministry of Food Processing Industries for ₹1,000 crore investment across six statesGroup capex
19 Sep 2025Delhi HC division bench warns PAL of costs on its appeal against the Dabur injunction; matter adjourned to 23 Sep–
27 Sep 2025PFL AGM: Swami Ramdev re-appointed director; Walker Chandiok joint auditor; revised RPT limit with PALGovernance at affiliate
6/11 Nov 2025Delhi HC (Justice Tejas Karia) restrains PAL's "dhoka" chyawanprash ad; platforms ordered to block it within three daysSecond chyawanprash injunction in four months
Dec 2025PFL CEO sets FY2026 targets (HPC 10–12%; foods 6–8%)Operating guidance
6 Dec 2025MoU with the Russian governmentInternational expansion
Dec 2025Tripura government partnership (₹300–400 crore)Regional investment
22 Jan 2026Patanjali Emergency & Critical Care Hospital, Haridwar, inaugurated by Amit ShahHealthcare diversification
9 Feb 2026Block deal: 1.48% of PFL (53.6 lakh shares; ₹272 crore at ~₹509)Selling pressure on the affiliate
12 Mar 2026IRDAI grants extension on the Magma applicationRegulatory delay
May 2026PFL receives a ₹1,352.92 crore GST show-cause notice (FY2023); reportedly dropped June 2026–
30 May 2026PFL FY2026 results: revenue ₹40,169.58 crore (+19%); PAT ₹1,814 crore (incl. ₹788 crore tax refund); Q4 EBITDA margin 4.0%Margin compression evident
30 Jun 2026ICRA upgrades PFL long-term rating to AA- (Stable)Credit positive for the group
15 Jul 2026PFL shares fall ~19–20% intraday to ₹328 (52-week/six-year low) after a ₹195 crore block deal (1.5% equity); company says no undisclosed material event~₹37,132 crore market cap; down ~37–38% YTD
28 Jul 2026IRDAI approves PAL (73.56%) and DS Group (24.5%) acquisition of Magma; valid three monthsFinal regulatory hurdle
Aug 2026PFL Q1 FY2027: consolidated PAT ₹335.73 crore (+86% YoY); total income ₹11,341.89 croreAffiliate earnings rebound
5 Sep 2026PFL publishes FY2026 annual report (₹5/share total dividend; ICRA AA-)Disclosure
25 Sep 2026Uttarakhand CM Pushkar Dhami opens a Patanjali Ayurveda Gurukulam (group education initiative)Group soft-infrastructure
by ~28 Oct 2026Deadline under the IRDAI approval window to complete the Magma transactionKey near-term catalyst

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Income Statement: Revenue & Gross Profit: Revenue from operations fell from INR 98.1 Bn in FY2021 to INR 58.6 Bn in FY2025.
Patanjali Ayurved Limited — Income Statement: Revenue & Gross Profit
Series (INR Bn)FY2021FY2022FY2023FY2024FY2025
Revenue from operations98.1106.675.364.658.6

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Patanjali Ayurved Limited, Annual Report FY2021-22 (Board's Report, AOC-1, Secretarial Audit) — patanjaliayurved.org
  2. Patanjali Ayurved Limited, Annual Report FY2020-21 — patanjaliayurved.org
  3. PTI / Business Standard / Tofler: PAL FY2023–FY2024 RoC financials (Nov 2024) · FY2020 financials (Nov 2020)
  4. BloombergQuint: PAL FY2021 segment data
  5. TheCompanyCheck / Tracxn: registry data (CIN, registered office, FY2025 revenue)
  6. Wikipedia: Patanjali Ayurved · Balkrishna · Patanjali Foods (used for dated events, cross-checked where possible)
  7. CARE Ratings press release (Apr/Oct 2019): ICRA via PTI (Jan 2017) · Business Standard / Bloomberg (Oct–Dec 2019)
  8. Business Standard, Moneylife, NewsBytes, GKToday, Insurance Business, Angel One, Storyboard18, The Week/PTI: Magma General Insurance transaction (Mar 2025 – Jul 2026)
  9. Bloomberg / Outlook Business / Business Today / Storyboard18: MCA notice report and denial (May–Jun 2025)
  10. Exchange4media, Social Samosa, The News Minute, PTI, SCC Online, Bar & Bench via Moneylife, Angel One: Dabur litigation (Jul–Nov 2025)
  11. The Wire, Scroll, PTI, ETV Bharat: Hamdard litigation (Apr–May 2025)
  12. All India Radio, Business Standard, Times of Oman, Curly Tales: Nagpur MIHAN park (Mar 2025)
  13. PFL filings via FilingReader, ICICI Direct, ScanX, Kotak Neo, Outlook Business, Business Today, DSIJ/Bajaj Broking, Angel One, marketsmojo, AlphaStreet, The Consumer Daily (FY2024 – Q1 FY2027)
  14. Peer data: Dabur (Investywise AGM summary · Stockanalysis · Angel One), Emami (Free Press Journal · FilingReader), Colgate-Palmolive India (Reuters via Zerodha)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.